Hepatobiliary Adverse Drug Reactions Associated With Remdesivir: The WHO International Pharmacovigilance Study - Archive ouverte HAL
Article Dans Une Revue Clinical Gastroenterology and Hepatology Année : 2021

Hepatobiliary Adverse Drug Reactions Associated With Remdesivir: The WHO International Pharmacovigilance Study

Se Yong Jung
Seung Won Lee
  • Fonction : Auteur
Sung Hwi Hong
  • Fonction : Auteur
Hanna Kim
  • Fonction : Auteur
Jae Il Shin
  • Fonction : Auteur

Résumé

Remdesivir has demonstrated clinical benefits in randomized placebo-controlled trials (RCTs) in patients with coronavirus disease 2019 (COVID-19)1-4 and was first approved for COVID-19 patients.5 However, whether remdesivir causes gastrointestinal adverse drug reaction (GI-ADRs) including hepatotoxicity is less clear.1-4,6 Therefore, we aimed to detect a diverse spectrum of GI-ADRs associated with remdesivir using VigiBase, the World Health Organization's international pharmacovigilance database of individual case safety reports.

Dates et versions

hal-04002867 , version 1 (23-02-2023)

Identifiants

Citer

Min Seo Kim, Se Yong Jung, Seung Won Lee, Han Li, Ai Koyanagi, et al.. Hepatobiliary Adverse Drug Reactions Associated With Remdesivir: The WHO International Pharmacovigilance Study. Clinical Gastroenterology and Hepatology, 2021, 19 (9), pp.1970-1972.e3. ⟨10.1016/j.cgh.2021.04.039⟩. ⟨hal-04002867⟩
18 Consultations
0 Téléchargements

Altmetric

Partager

More